Under pathological conditions such as DM and fatty liver, oxidized low-density lipoprotein can induce an increase in PPAR-γ through the PKC-α/ERK/PPAR-γ pathway (Hashimoto et al., 2000; Neuschwander-Tetri and Caldwell, 2003), which can inhibit the susceptibility of PPAR-γ and the expression of its target genes in a dose-dependent manner (Cen et al., 2013). This evidence concerns the gene PPARG and Hepatic steatosis.